Mercer Global Advisors’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-12,755
Closed -$16.6K – 3857
2026
Q2
$16.6K Buy
+12,755
New +$20.3K ﹤0.01% 3604
2023
Q1
– Sell
-147,857
Closed -$207K – 1953
2022
Q4
$207K Hold
147,857
– – ﹤0.01% 1698
2022
Q3
$228K Hold
147,857
– – ﹤0.01% 1566
2022
Q2
$325K Hold
147,857
– – ﹤0.01% 1386
2022
Q1
$367K Sell
147,857
-40,500
-22% -$143K ﹤0.01% 1401
2021
Q4
$1.13M Buy
188,357
+15,000
+9% +$89.4K 0.01% 830
2021
Q3
$1.16M Buy
173,357
+5,500
+3% +$34.6K 0.01% 793
2021
Q2
$1.12M Buy
167,857
+10,000
+6% +$84.8K 0.01% 786
2021
Q1
$1.46M Buy
157,857
+22,007
+16% +$267K 0.01% 642
2020
Q4
$2.44M Hold
135,850
– – 0.03% 374
2020
Q3
$1.93M Buy
135,850
+200
+0.1% +$1.32K 0.03% 392
2020
Q2
$680K Buy
+135,650
New +$278K 0.01% 580

Other funds holding CRDF

Mercer Global Advisors's CRDF Position: Q3 2026 in Review

Mercer Global Advisors sold out of Cardiff Oncology (CRDF) in Q3 2026, closing a stake of 12,755 shares — an estimated $16.6K sold.

Mercer Global Advisors first reported a position in CRDF in Q2 2020 and held it in 12 quarters. The position peaked at $2.44M in Q4 2020. 75 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • Mercer Global Advisors reported no remaining Cardiff Oncology position as of Q3 2026 after selling out during the quarter.
  • Mercer Global Advisors sold 12,755 Cardiff Oncology shares in Q3 2026, an estimated $16.6K.
  • Mercer Global Advisors first reported a position in Cardiff Oncology in Q2 2020 and held it in 12 quarters.
  • Mercer Global Advisors's Cardiff Oncology position peaked at $2.44M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.